A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment.

Trial Profile

A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Atazanavir; Cobicistat; Darunavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jul 2014 Planned End Date changed from 1 Jun 2014 to 1 Dec 2014 as reported by the ClinicalTrials.gov .
    • 10 Jan 2014 Planned End Date changed from 1 Mar 2014 to 1 Jun 2014 as reported by the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top